Trovagene Announces Leadership Change

SAN DIEGO, June 22, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced that William Welch has resigned from his positions as Chief Ex...